Aethlon Medical has enrolled the first patient in its Australian clinical trial evaluating the safety, feasibility, and ...

The Safety Review Committee approved enrollment of the next higher-dose cohorts as follows: Cohort 3: 120 microgram/kg Q2W MDNA11 and 400 mg Q6W KEYTRUDA; Cohort 4: 120 microgram/kg Q3W MDNA11 and 400 ...

We recently compiled a list of the 10 Best Low Volatility Stocks to Invest in Now. In this article, we are going to take a ...

The safety and overall survival seen in the ARC-10 trial lends further support to the firm's strategy of pairing domvanalimab and zimberelimab with chemo in STAR-121.

M uch to the chagrin of investors looking to get rich quickly with a biopharma investment, the drug development cycle is, by ...

Keytruda in early-stage triple-negative breast cancer led to immune-related adverse effects, including severe GI issues and ...

The top-line beat was led by its higher than anticipated sales of Covid-19 vaccine, while its recently approved respiratory syncytial virus vaccine raked in just $10 ...

Merck's consistent dividend payments over 34 years, healthy balance sheet, and attractive valuation highlight its investment ...

IO Biotech (IOBT) announced data from the NSCLC cohort in the company’s Phase 2 basket trial of IO102-IO103, the company’s lead investigational candidate, given in combination with Merck’s anti-PD-1 ...

Merck (NYSE: MRK) recently reported its Q3 results, with revenues and earnings exceeding the street estimates.

The whole-exome sequencing and whole-transcriptome sequencing-based test is approved for molecular profiling of solid tumors.